ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today announced its interim results for the six months ended 30 June 2019. Commenting on the statement and outlook
The Life Sciences Division’s Navid Malik discusses ImmuPharma plc in this exclusive interview with DirectorsTalk
ImmuPharma plc (LON: IMM) is the topic of conversation when Navid Malik Executive Director at The Life Sciences Division joins DirectorsTalk. Navid provides some background to TLSD and it’s interest in
The Life Sciences Division (TLSD), a specialist investment bank to global life sciences companies, today announced an update report on ImmuPharma plc (LON:IMM), a pharmaceutical development company listed on AIM
Tim McCarthy, Chairman added: “”We are delighted that Lupuzor™ has again confirmed its robust safety profile and we are confident that Lupuzor™ has the potential to bring a much needed treatment
Commenting, ImmuPharma’s Chairman, Tim McCarthy, said: “We are delighted to be welcoming back Lanstead as a significant shareholder of the Company. Lanstead has been very supportive of the Company since
ImmuPharma’s Tim McCarthy discusses their final results, spend going forward, corporate strategy for Lupuzor, Nucant & Ureka, key milestones for shareholders and the initiation note issued by The Life Sciences Division in this exclusive interview with DirectorsTalk
ImmuPharma plc (LON: IMM) Chairman Tim McCarthy joins DirectorsTalk to discuss final results for the twelve months ended 31 December 2018. Tim talks us through the financial highlights, including the loss
ImmuPharma PLC (LON:IMM,, the specialist drug discovery and development company, today announced its final results for the twelve months ended 31 December 2018 . Commenting on the statement and outlook
ImmuPharma PLC (LON: IMM), the specialist drug discovery and development company has today provided the following update on ongoing activities. Lupuzor™ Lupuzor™ is the Company’s late stage asset for Lupus, a
© 2023 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
